Related Experiment Videos
Prognostic indications for Hürthle cell cancer
Yevgeniya Kushchayeva1, Quan-Yang Duh, Electron Kebebew
1Endocrine Surgical Oncology, Department of Surgery, University of California-San Francisco/Mount Zion Medical Center, 1600 Divisadero Street, San Francisco, CA 94143-1674, USA.
World Journal of Surgery
|November 2, 2004
Summary
Prognostic factors for Hürthle cell carcinoma (HCC) indicate that advanced tumor stage and male gender are associated with poorer outcomes in patients with this rare thyroid cancer.
Area of Science:
- Endocrinology
- Oncology
- Pathology
Background:
- Hürthle cell carcinoma (HCC) exhibits variable clinical behavior.
- Identifying key prognostic factors is crucial for managing HCC patients.
Purpose of the Study:
- To determine significant prognostic factors in patients diagnosed with Hürthle cell carcinoma.
- To analyze the impact of various clinical and pathological features on HCC patient outcomes.
Main Methods:
- Retrospective analysis of 33 Hürthle cell carcinoma patients treated between 1976 and 2002.
- Evaluation of patient demographics, tumor stage, presence of metastases, treatment details, and survival data.
Main Results:
- Male gender and advanced tumor stage (T4) were significantly associated with worse prognosis and increased mortality.
- While univariate analysis suggested poorer outcomes with less than total thyroidectomy, multivariate analysis did not confirm this.
- Five-year and ten-year cause-specific survival rates were 74% and 49%, respectively.
Conclusions:
- Gender and disease stage are critical determinants of prognosis in Hürthle cell carcinoma.
- Further research may refine treatment strategies based on these prognostic indicators.